CRCL With CRCL's markets relatively unproven, outcomes vary widely; SUSQ recommends waiting for a better entry point and maintain its $69 PT
CRCL With CRCL's markets relatively unproven, outcomes vary widely; SUSQ recommends waiting for a better entry point and maintain its $69 PT @ SUSQ
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.